Welcome!
Notice to Beneficiaries of the Veterans Health Administration: For questions pertaining to Health Care Benefits, please visit http://www.va.gov/health. Questions pertaining to your drug therapy or other medical questions should be referred directly to your Health Care Providers located at the VA facilities where you receive care.
For questions pertaining to prescription renewal, please visit MyHealtheVet
at https://www.myhealth.va.gov/. MyHealtheVet
provides access to trusted health information, links to Federal and VA benefits and resources, the Personal Health Journal, and now online VA prescription refill.
Mission: To improve the health status of veterans by encouraging the appropriate use of medications in a comprehensive medical care setting.
What is New at the PBM...
27 Jul 09 |
C1 Inhibitor Drug Monograph |
25 Jun 09 |
Ciclesonide Drug Monograph |
08 Jun 09 |
Aprepitant Criteria for Formulary Use |
08 Jun 09 |
Aprepitant Drug Monograph |
18 May 09 |
Drotrecogin Alfa Criteria for Non-Formulary Use |
15 Apr 09 |
Alvimopan Monograph |
15 Apr 09 |
Alvimopan, Criteria for Nonformulary Use |
24 Mar 09 |
Regadenoson, Drug Monograph |
11 Mar 09 |
Phosphate Binder (Lanthanum, Sevelamer), Criteria for Formulary Use |
03 Mar 09 |
VHA Handbook 1108.08: VHA Formulary Management Process |
07 Jan 09 |
Chronic Heart Failure (Pharmacologic Management), VA DoD Clinical Practice Guideline, Treatment Guideline Added |
07 Jan 09 |
Kidney Dysfunction, Clinical Recommendations, FAQ Sheet Added |
07 Jan 09 |
Hyaluronidase (Amphadase, Hydase, Vitrase, Hylenex), Drug Monograph |
10 Dec 08 |
Montelukast, Criteria for Use |
05 Dec 08 |
VA/VHA USP 797 Pharmacy Design Guidance (Environmental and Architectural Cleanroom Design Document) - May 2008, Links & Other Resources |
04 Dec 08 |
Phosphate binder (Lanthanum, Sevelamer), Criteria for Use |
20 Nov 08 |
Cilostazol, Criteria for Use |
06 Nov 08 |
Zoledronic Acid (Reclast), Criteria for Use |
06 Nov 08 |
Zoledronic Acid (Reclast), Drug Monograph |
21 Oct 08 |
Endothelin Receptor Antagonists (ERA), Criteria for Use |
21 Oct 08 |
Ambrisentan, Drug Monograph |
15 Sep 08 |
Hyaluronic acid-Hylan G-F 20 for Osteoarthritis of the Knee, Drug Class Review |
15 Sep 08 |
Hyaluronic Acid-Hylan G-F 20, Criteria for Use |
15 Sep 08 |
Varenicline Criteria for Prescribing, Criteria for Use |
Michael A. Valentino, R. Ph., MHSA |
Chief Consultant |
Virginia Torrise, Pharm. D. |
Deputy Chief Consultant |
Timothy J. Stroup, R. Ph. |
Deputy Chief Consultant - CMOP Planning and Program Development |
Ken Siehr, R.Ph. MS |
Deputy Chief Consultant- CMOP Operations |
Joseph J. Canzolino, R. Ph. |
Deputy Chief Consultant |
Vincent Calabrese, Pharm D. |
Assistant Chief Consultant |
If you have a question pertaining to this website and only information contained in this website, please contact the PBM Webmaster. Please note: For questions pertaining to Health Care Benefits, please visit http://www.va.gov/Health_Benefits/. For questions pertaining to prescription renewal, please visit https://www.myhealth.va.gov/. Questions pertaining to your drug therapy or other medical questions should be referred directly to your Health Care Providers located at the VA facilities where you receive care.
|